Compare ARDX & AORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | AORT |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2014 | 1996 |
| Metric | ARDX | AORT |
|---|---|---|
| Price | $5.09 | $27.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $15.14 | ★ $49.40 |
| AVG Volume (30 Days) | ★ 3.4M | 553.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.62 |
| EPS | N/A | ★ 0.03 |
| Revenue | $2,607,000.00 | ★ $298,836,000.00 |
| Revenue This Year | $37.75 | $14.20 |
| Revenue Next Year | $34.24 | $11.20 |
| P/E Ratio | ★ N/A | $870.00 |
| Revenue Growth | N/A | ★ 18.01 |
| 52 Week Low | $4.08 | $19.16 |
| 52 Week High | $8.40 | $48.25 |
| Indicator | ARDX | AORT |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 66.63 |
| Support Level | $4.95 | $19.49 |
| Resistance Level | $5.34 | $37.65 |
| Average True Range (ATR) | 0.17 | 0.93 |
| MACD | 0.01 | 0.24 |
| Stochastic Oscillator | 21.12 | 83.70 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.